Last reviewed · How we verify
Influenza-like symptoms — Treatment Landscape & Competitive Intelligence
10 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Propadrine | PHENYLPROPANOLAMINE | Alpharma Us Pharms | Indirectly Acting Sympathomimetic Amines | Sodium-dependent noradrenaline transporter | 2000-01-01 | |
| Sudafed | pseudoephedrine | Generic (multiple manufacturers) | Nasal decongestant (sympathomimetic) | Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor | 1976-01-01 | |
| Sudafed PE | phenylephrine | Generic (multiple manufacturers) | Alpha-1 adrenergic agonist (decongestant/vasopressor) | Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor | 1976-01-01 | |
| Pyrilamine | mepyramine | Impax Labs | Central Nervous System Stimulant [EPC] | Histamine H1 receptor | 1973-01-01 | |
| Advil | ibuprofen | Generic (originally Boots Group) | Nonsteroidal Anti-inflammatory Drug [EPC] | Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2 | 1969-01-15 | |
| Acetaminophen | Paracetamol | Polymedica | acetaminophen | Transient receptor potential cation channel subfamily V member 4 | 1968-01-01 | |
| Drixoral | DEXBROMPHENIRAMINE | Merck & Co. | dexbrompheniramine | Histamine H1 receptor | 1963-01-01 | |
| Delsym | dextromethorphan | Generic (originally Roche) | Antitussive (non-opioid) | Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6 | 1958-01-01 | |
| Mucinex | guaifenesin | Generic (multiple manufacturers) | Expectorant [EPC] | Vagal gastric reflex → increased respiratory secretions | 1952-01-01 | |
| Phenergan Vc W/ Codeine | PHENYLEPHRINE BITARTRATE | ANI Pharmaceuticals | Nonsteroidal Anti-inflammatory Drug [EPC] | Alpha-1B adrenergic receptor | 1952-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (multiple manufacturers) · 4 drugs in Influenza-like symptoms
- · 3 drugs in Influenza-like symptoms
- Bayer · 2 drugs in Influenza-like symptoms
- Chattem · 1 drug in Influenza-like symptoms
- Endo · 1 drug in Influenza-like symptoms
- Generic (originally Boots Group) · 1 drug in Influenza-like symptoms
- Generic (originally Roche) · 1 drug in Influenza-like symptoms
- Hikma · 1 drug in Influenza-like symptoms
- Impax Labs · 1 drug in Influenza-like symptoms
- Merck & Co. · 1 drug in Influenza-like symptoms
- Polymedica · 1 drug in Influenza-like symptoms
- St. Petersburg Bekhterev Research Psychoneurological Institute · 1 drug in Influenza-like symptoms
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Influenza-like symptoms:
- Influenza-like symptoms treatment updates — RSS
- Influenza-like symptoms treatment updates — Atom
- Influenza-like symptoms treatment updates — JSON
Cite this brief
Drug Landscape (2026). Influenza-like symptoms — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/influenza-like-symptoms. Accessed 2026-06-10.
Related
- Influenza-like symptoms full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing